{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:13:00Z","timestamp":1792059180386,"version":"4.4.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T00:00:00Z","timestamp":1474934400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s11940-016-0427-0","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T09:25:40Z","timestamp":1474968340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Treatment Options for Urogenital Dysfunction in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"18","author":[{"given":"Amit","family":"Batla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Tayim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahreen","family":"Pakzad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalesh N.","family":"Panicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,27]]},"reference":[{"issue":"3","key":"427_CR1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical E. Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235\u201345.","journal-title":"Lancet Neurol"},{"issue":"2","key":"427_CR2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/mds.26077","volume":"30","author":"C Pont-Sunyer","year":"2015","unstructured":"Pont-Sunyer C, Hotter A, Gaig C, Seppi K, Compta Y, Katzenschlager R, et al. The onset of nonmotor symptoms in Parkinson\u2019s disease (the ONSET PD study). Move dis: off J Move Dis Soc. 2015;30(2):229\u201337.","journal-title":"Move dis: off J Move Dis Soc"},{"key":"427_CR3","doi-asserted-by":"crossref","unstructured":"Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T. Pathophysiology of bladder dysfunction in Parkinson\u2019s disease. Neurobiol Dis. 2011.","DOI":"10.4061\/2011\/924605"},{"issue":"1","key":"427_CR4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF02089401","volume":"17","author":"JT Andersen","year":"1985","unstructured":"Andersen JT. Disturbances of bladder and urethral function in Parkinson\u2019s disease. Int Urol Nephrol. 1985;17(1):35\u201341.","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"427_CR5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.nbd.2011.10.002","volume":"46","author":"R Sakakibara","year":"2012","unstructured":"Sakakibara R, Tateno F, Kishi M, Tsuyuzaki Y, Uchiyama T, Yamamoto T. Pathophysiology of bladder dysfunction in Parkinson\u2019s disease. Neurobiol Dis. 2012;46(3):565\u201371.","journal-title":"Neurobiol Dis"},{"issue":"4","key":"427_CR6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0022-5347(17)43390-8","volume":"138","author":"Y Berger","year":"1987","unstructured":"Berger Y, Blaivas JG, DeLaRocha ER, Salinas JM. Urodynamic findings in Parkinson\u2019s disease. J Urol. 1987;138(4):836\u20138.","journal-title":"J Urol"},{"issue":"2","key":"427_CR7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s10286-005-0253-z","volume":"15","author":"C Magerkurth","year":"2005","unstructured":"Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson\u2019s disease: prevalence and impact on daily life. Clin Auton Res. 2005;15(2):76\u201382.","journal-title":"Clin Auton Res"},{"issue":"11","key":"427_CR8","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1007\/s00415-005-0855-3","volume":"252","author":"Y Balash","year":"2005","unstructured":"Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N. Falls in outpatients with Parkinson\u2019s disease: frequency, impact and identifying factors. J Neurol. 2005;252(11):1310\u20135.","journal-title":"J Neurol"},{"issue":"3","key":"427_CR9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/jech.44.3.246","volume":"44","author":"CW McGrother","year":"1990","unstructured":"McGrother CW, Jagger C, Clarke M, Castleden CM. Handicaps associated with incontinence: implications for management. J Epidemiol Community Health. 1990;44(3):246\u20138.","journal-title":"J Epidemiol Community Health"},{"issue":"5","key":"427_CR10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.eururo.2012.07.004","volume":"62","author":"JN Cornu","year":"2012","unstructured":"Cornu JN, Abrams P, Chapple CR, Dmochowski RR, Lemack GE, Michel MC, et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management\u2014a systematic review and meta-analysis. Eur Urol. 2012;62(5):877\u201390.","journal-title":"Eur Urol"},{"issue":"6","key":"427_CR11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mds.20867","volume":"21","author":"K Winge","year":"2006","unstructured":"Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Dis: Off J Move Dis Soc. 2006;21(6):737\u201345.","journal-title":"Mov Dis: Off J Move Dis Soc"},{"issue":"5","key":"427_CR12","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3760\/cma.j.issn.0366-6999.20132695","volume":"127","author":"P Xue","year":"2014","unstructured":"Xue P, Wang T, Zong H, Zhang Y. Urodynamic analysis and treatment of male Parkinson\u2019s disease patients with voiding dysfunction. Chin Med J. 2014;127(5):878\u201381.","journal-title":"Chin Med J"},{"issue":"1\u20132","key":"427_CR13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1566-0702(01)00295-8","volume":"92","author":"R Sakakibara","year":"2001","unstructured":"Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M, Yoshiyama M, et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson\u2019s disease. Aut Neurosci: Basic Clin. 2001;92(1\u20132):76\u201385.","journal-title":"Aut Neurosci: Basic Clin"},{"issue":"6","key":"427_CR14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1464-410X.1985.tb07025.x","volume":"57","author":"H Fitzmaurice","year":"1985","unstructured":"Fitzmaurice H, Fowler CJ, Rickards D, Kirby RS, Quinn NP, Marsden CD, et al. Micturition disturbance in Parkinson\u2019s disease. Br J Urol. 1985;57(6):652\u20136.","journal-title":"Br J Urol"},{"issue":"3","key":"427_CR15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/nau.20026","volume":"23","author":"AL Dalmose","year":"2004","unstructured":"Dalmose AL, Bjarkam CR, Sorensen JC, Djurhuus JC, Jorgensen TM. Effects of high frequency deep brain stimulation on urine storage and voiding function in conscious minipigs. Neurourol Urodyn. 2004;23(3):265\u201372.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"427_CR16","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0306-4522(03)00319-1","volume":"120","author":"R Sakakibara","year":"2003","unstructured":"Sakakibara R, Nakazawa K, Uchiyama T, Yoshiyama M, Yamanishi T, Hattori T. Effects of subthalamic nucleus stimulation on the micturation reflex in cats. Neuroscience. 2003;120(3):871\u20135.","journal-title":"Neuroscience"},{"issue":"1","key":"427_CR17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.neuroscience.2005.06.007","volume":"135","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto T, Sakakibara R, Hashimoto K, Nakazawa K, Uchiyama T, Liu Z, et al. Striatal dopamine level increases in the urinary storage phase in cats: an in vivo microdialysis study. Neuroscience. 2005;135(1):299\u2013303.","journal-title":"Neuroscience"},{"issue":"11","key":"427_CR18","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1468-1331.2005.01087.x","volume":"12","author":"K Winge","year":"2005","unstructured":"Winge K, Friberg L, Werdelin L, Nielsen KK, Stimpel H. Relationship between nigrostriatal dopaminergic degeneration, urinary symptoms, and bladder control in Parkinson\u2019s disease. Eur J Neurol. 2005;12(11):842\u201350.","journal-title":"Eur J Neurol"},{"issue":"1","key":"427_CR19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1464-410X.2011.10175.x","volume":"108","author":"JP Weiss","year":"2011","unstructured":"Weiss JP, Blaivas JG, Bliwise DL, Dmochowski RR, Dubeau CE, Lowe FC, et al. The evaluation and treatment of nocturia: a consensus statement. BJU Int. 2011;108(1):6\u201321.","journal-title":"BJU Int"},{"issue":"6","key":"427_CR20","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/1756285611411504","volume":"4","author":"G Bronner","year":"2011","unstructured":"Bronner G, Vodusek DB. Management of sexual dysfunction in Parkinson\u2019s disease. Ther Adv Neurol Disord. 2011;4(6):375\u201383.","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"427_CR21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.4088\/JCP.11ac07093","volume":"72","author":"P Gerretsen","year":"2011","unstructured":"Gerretsen P, Pollock BG. Rediscovering adverse anticholinergic effects. J Clin Psychiatry. 2011;72(6):869\u201370.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"427_CR22","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/mdc3.12279","volume":"3","author":"M Smith","year":"2016","unstructured":"Smith M, Seth J, Batla A, Hofereiter J, Bhatia KP, Panicker JN. Nocturia in patients with Parkinson\u2019s disease. Move Dis Clin Pract. 2016;3(2):168\u201372. This recently published study highlights the importance of bladder diaries in identifying causes of nocturia in Parkinson\u2019s disease.","journal-title":"Move Dis Clin Pract"},{"key":"427_CR23","doi-asserted-by":"crossref","unstructured":"Phe V, Pakzad M, Curtis C, Porter B, Haslam C, Chataway J, et al. Urinary tract infections in multiple sclerosis. Mult Scler. 2016.","DOI":"10.1177\/1352458516633903"},{"issue":"7","key":"427_CR24","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S1474-4422(15)00070-8","volume":"14","author":"JN Panicker","year":"2015","unstructured":"Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015;14(7):720\u201332. This review article summarizes problems with management of LUT dysfunction and highlights the troubles with cholinergic burden in the elderly population.","journal-title":"Lancet Neurol"},{"key":"427_CR25","doi-asserted-by":"crossref","unstructured":"Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H, The Parkinson\u2019s Disease Subcomittee TNPCiTICS. A guideline for the management of bladder dysfunction in Parkinson\u2019s disease and other gait disorders. Neurourol Urodynamics. 2015.","DOI":"10.1002\/nau.22764"},{"key":"427_CR26","unstructured":"NICE. Urinary incontinence in neurological disease: Management of lower urinary tract dysfunction in neurological disease. 2012. National guidelines that summarize the approach to investigations and treatment of urinary incontinence in neurological diseases including PD."},{"issue":"6","key":"427_CR27","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.eururo.2012.08.060","volume":"62","author":"N Buser","year":"2012","unstructured":"Buser N, Ivic S, Kessler TM, Kessels AG, Bachmann LM. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol. 2012;62(6):1040\u201360. This article discusses the role of daily fluid intake and its effects on nocturia.","journal-title":"Eur Urol"},{"issue":"1","key":"427_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/nau.1930120102","volume":"12","author":"DJ Griffiths","year":"1993","unstructured":"Griffiths DJ, McCracken PN, Harrison GM, Gormley EA. Relationship of fluid intake to voluntary micturition and urinary incontinence in geriatric patients. Neurourol Urodyn. 1993;12(1):1\u20137.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"427_CR29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0022-5347(05)67961-X","volume":"163","author":"JP Weiss","year":"2000","unstructured":"Weiss JP, Blaivas JG. Nocturia. J Urol. 2000;163(1):5\u201312.","journal-title":"J Urol"},{"key":"427_CR30","doi-asserted-by":"crossref","unstructured":"Batla A, Ph\u00e9 V, De Min L, Panicker JN. Nocturia in Parkinson\u2019s disease: why does it occur and how to manage? Movement Disorders Clinical Practice. 2016: (online ahead of print). This article summarizes the management of nocturia in PD.","DOI":"10.1002\/mdc3.12374"},{"issue":"4","key":"427_CR31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.urology.2005.10.061","volume":"67","author":"R Rackley","year":"2006","unstructured":"Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology. 2006;67(4):731\u20136. discussion 6.","journal-title":"Urology"},{"issue":"5","key":"427_CR32","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2012.02.036","volume":"62","author":"P Madhuvrata","year":"2012","unstructured":"Madhuvrata P, Singh M, Hasafa Z, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol. 2012;62(5):816\u201330.","journal-title":"Eur Urol"},{"issue":"3","key":"427_CR33","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","volume":"175","author":"SL Gray","year":"2015","unstructured":"Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Int Med. 2015;175(3):401\u20137.","journal-title":"JAMA Int Med"},{"issue":"8","key":"427_CR34","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s12603-009-0196-5","volume":"13","author":"AT Isik","year":"2009","unstructured":"Isik AT, Celik T, Bozoglu E, Doruk H. Trospium and cognition in patients with late onset Alzheimer disease. J Nutr Health Aging. 2009;13(8):672\u20136.","journal-title":"J Nutr Health Aging"},{"issue":"5","key":"427_CR35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.parkreldis.2015.02.025","volume":"21","author":"TA Zesiewicz","year":"2015","unstructured":"Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2015;21(5):514\u201320. This is the only double-blind, randomized, placebo-controlled study evaluating an antimuscarinic agent in PD.","journal-title":"Parkinsonism Relat Disord"},{"key":"427_CR36","unstructured":"Urinary Incontinence UK: BNF; 2016. Available from: http:\/\/www.evidence.nhs.uk\/formulary\/bnf\/current\/7-obstetrics-gynaecology-and-urinary-tract-disorders\/74-drugs-for-genito-urinary-disorders\/742-drugs-for-urinary-frequency-enuresis-and-incontinence\/urinary-incontinence ."},{"issue":"6","key":"427_CR37","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/mds.20867","volume":"21","author":"K Winge","year":"2006","unstructured":"Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord. 2006;21(6):737\u201345.","journal-title":"Mov Disord"},{"issue":"3","key":"427_CR38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/08998280.2007.11928310","volume":"20","author":"K Hesch","year":"2007","unstructured":"Hesch K. Agents for treatment of overactive bladder: a therapeutic class review. Proc (Baylor Univ Med Cent). 2007;20(3):307\u201314.","journal-title":"Proc (Baylor Univ Med Cent)"},{"issue":"5","key":"427_CR39","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0022-5347(17)45940-4","volume":"135","author":"JB Gajewski","year":"1986","unstructured":"Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol. 1986;135(5):966\u20138.","journal-title":"J Urol"},{"key":"427_CR40","doi-asserted-by":"crossref","first-page":"834753","DOI":"10.1155\/2011\/834753","volume":"2011","author":"F Rey van","year":"2011","unstructured":"van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol. 2011;2011:834753.","journal-title":"Adv Urol"},{"key":"427_CR41","unstructured":"Batla A, Panicker JN. Lower urinary tract dysfunction in Parkinson\u2019s disease and multiple system atrophy. Leading Opin Urol. 2013;17\u201322. This article summarizes common causes and management options for urinary dysfunction in PD and MSA."},{"issue":"3","key":"427_CR42","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/10790268.2004.11753751","volume":"27","author":"KD Ethans","year":"2004","unstructured":"Ethans KD, Nance PW, Bard RJ, Casey AR, Schryvers OI. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med. 2004;27(3):214\u20138.","journal-title":"J Spinal Cord Med"},{"key":"427_CR43","unstructured":"Mazo EB, Babanina GA. [Trospium chloride (spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions]. Urologiia. 2007. (3):15\u20139."},{"issue":"2","key":"427_CR44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","volume":"82","author":"S Herschorn","year":"2013","unstructured":"Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313\u201320.","journal-title":"Urology"},{"issue":"13","key":"427_CR45","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.purol.2015.08.260","volume":"25","author":"V Phe","year":"2015","unstructured":"Phe V, Mukhtar B, Couchman A, Grewal M, Hamid R, Ockrim J, et al. Progres Urol: J Assoc Fr Urol Soc Fr Urol. 2015;25(13):845\u20136.","journal-title":"Progres Urol: J Assoc Fr Urol Soc Fr Urol"},{"key":"427_CR46","unstructured":"Mirabegron (Betmiga\u25bc): risk of severe hypertension and associated cerebrovascular and cardiac events: Medicines and Healthcare products Regulatory Agency; 2015 [updated 14 October 2015]. Available from: https:\/\/www.gov.uk\/drug-safety-update\/mirabegron-betmiga-risk-of-severe-hypertension-and-associated-cerebrovascular-and-cardiac-events ."},{"issue":"3","key":"427_CR47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/mds.870100318","volume":"10","author":"O Suchowersky","year":"1995","unstructured":"Suchowersky O, Furtado S, Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson\u2019s disease. Move Dis: Off J Move Dis Soc. 1995;10(3):337\u201340. An open label study that identified nocturnal polyuria as an important problem in PD which was treatable with intranasal desmopressin in all the patients who completed the study.","journal-title":"Move Dis: Off J Move Dis Soc"},{"issue":"9","key":"427_CR48","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1464-410X.2002.02791.x","volume":"89","author":"A Mattiasson","year":"2002","unstructured":"Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int. 2002;89(9):855\u201362.","journal-title":"BJU Int"},{"issue":"1","key":"427_CR49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.urology.2013.09.017","volume":"83","author":"RU Anderson","year":"2014","unstructured":"Anderson RU, Orenberg EK, Glowe P. OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson\u2019s disease. Urology. 2014;83(1):22\u20137. Double blind placebo controlled trial of oral desmopressin in men with nocturia showing improvement.","journal-title":"Urology"},{"issue":"3","key":"427_CR50","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.juro.2011.04.071","volume":"186","author":"A Giannantoni","year":"2011","unstructured":"Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, et al. Botulinum toxin type A in patients with Parkinson\u2019s disease and refractory overactive bladder. J Urol. 2011;186(3):960\u20134.","journal-title":"J Urol"},{"issue":"8","key":"427_CR51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.parkreldis.2010.06.006","volume":"16","author":"H Kulaksizoglu","year":"2010","unstructured":"Kulaksizoglu H, Parman Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2010;16(8):531\u20134.","journal-title":"Parkinsonism Relat Disord"},{"key":"427_CR52","first-page":"191","volume":"8","author":"JH Seth","year":"2014","unstructured":"Seth JH, Haslam C, Panicker JN. Ensuring patient adherence to clean intermittent self-catheterization. Patient Preference Adherence. 2014;8:191\u20138. This study evaluated the use of Intradetrusor injections of botulinum toxin in 16 patients with PD with improvements in quality of life.","journal-title":"Patient Preference Adherence"},{"issue":"1","key":"427_CR53","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/nau.20593","volume":"28","author":"SC Kabay","year":"2009","unstructured":"Kabay SC, Kabay S, Yucel M, Ozden H. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson\u2019s disease. Neurourol Urodyn. 2009;28(1):62\u20137.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"427_CR54","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/WON.0000000000000078","volume":"42","author":"MC Perissinotto","year":"2015","unstructured":"Perissinotto MC, D\u2019Ancona CA, Lucio A, Campos RM, Abreu A. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease: a randomized controlled trial. J Wound, Ostomy, Continence Nurse: Off Publ Wound, Ostomy Continence Nurse Soc\/WOCN. 2015;42(1):94\u20139.","journal-title":"J Wound, Ostomy, Continence Nurse: Off Publ Wound, Ostomy Continence Nurse Soc\/WOCN"},{"issue":"6","key":"427_CR55","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.eururo.2010.09.024","volume":"58","author":"TM Kessler","year":"2010","unstructured":"Kessler TM, La Framboise D, Trelle S, Fowler CJ, Kiss G, Pannek J, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58(6):865\u201374.","journal-title":"Eur Urol"},{"issue":"7","key":"427_CR56","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/nau.20054","volume":"23","author":"K Winge","year":"2004","unstructured":"Winge K, Werdelin LM, Nielsen KK, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson\u2019s disease. Neurourol Urodyn. 2004;23(7):689\u201396.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"427_CR57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.parkreldis.2003.08.001","volume":"10","author":"S Kuno","year":"2004","unstructured":"Kuno S, Mizuta E, Yamasaki S, Araki I. Effects of pergolide on nocturia in Parkinson\u2019s disease: three female cases selected from over 400 patients. Parkinsonism Relat Disord. 2004;10(3):181\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"427_CR58","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/ana.10806","volume":"55","author":"C Seif","year":"2004","unstructured":"Seif C, Herzog J, van der Horst C, Schrader B, Volkmann J, Deuschl G, et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol. 2004;55(1):118\u201320.","journal-title":"Ann Neurol"},{"issue":"2","key":"427_CR59","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/mds.21253","volume":"22","author":"K Winge","year":"2007","unstructured":"Winge K, Nielsen KK, Stimpel H, Lokkegaard A, Jensen SR, Werdelin L. Lower urinary tract symptoms and bladder control in advanced Parkinson\u2019s disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord. 2007;22(2):220\u20135. In this series of 16 patients with PD who had subthalamic DBS, bladder sensitivity was shown to improve.","journal-title":"Mov Disord"},{"issue":"4","key":"427_CR60","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1097\/01.ju.0000055520.88377.dc","volume":"169","author":"E Finazzi-Agro","year":"2003","unstructured":"Finazzi-Agro E, Peppe A, D\u2019Amico A, Petta F, Mazzone P, Stanzione P, et al. Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson\u2019s disease. J Urol. 2003;169(4):1388\u201391.","journal-title":"J Urol"},{"issue":"8","key":"427_CR61","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/nau.22237","volume":"31","author":"K Winge","year":"2012","unstructured":"Winge K, Nielsen KK. Bladder dysfunction in advanced Parkinson\u2019s disease. Neurourol Urodyn. 2012;31(8):1279\u201383.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"427_CR62","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0022-5347(17)41501-1","volume":"140","author":"DS Staskin","year":"1988","unstructured":"Staskin DS, Vardi Y, Siroky MB. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J Urol. 1988;140(1):117\u20138.","journal-title":"J Urol"},{"issue":"5","key":"427_CR63","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.juro.2009.01.049","volume":"181","author":"B Roth","year":"2009","unstructured":"Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and Parkinson\u2019s disease\u2014should transurethral resection of the prostate be avoided? J Urol. 2009;181(5):2209\u201313. A study of 50 patients with PD who had TURP suggesting increased risk of incontinence following prostatectomy in the parkinsonian patient with lack of voluntary sphincter control.","journal-title":"J Urol"},{"key":"427_CR64","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1017\/CBO9780511762611.012","volume-title":"Pelvic organ dysfunction in neurological disease: clinical management and rehabilitation","author":"C Chaliha","year":"2010","unstructured":"Chaliha C, Dalton CM, Elneil S, Kessler TM. Evaluation and management of neurogenic sexual dysfunction. In: Fowler CJ, Panicker JN, Emmanuel A, editors. Pelvic organ dysfunction in neurological disease: clinical management and rehabilitation. Cambridge: Cambridge University Press; 2010. p. 153\u201365."},{"key":"427_CR65","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/med\/9780199237234.003.0018","volume-title":"Non-motor symptoms of Parkinson\u2019s disease","author":"O Moore","year":"2009","unstructured":"Moore O, Bronner G, Giladi N. Sexuality in Parkinson\u2019s disease. In: Chaudhuri KR, editor. Non-motor symptoms of Parkinson\u2019s disease. Oxford: Oxford University Press; 2009. p. 225\u201340. This book chapter details the common sexual problems in PD and highlights the treatment options."},{"issue":"6","key":"427_CR66","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/1756285611411504","volume":"4","author":"G Tbronner","year":"2011","unstructured":"Tbronner G, Vodu\u0161ek DB. Management of sexual dysfunction in Parkinson\u2019s disease. Ther Adv Neurol Disord. 2011;4(6):375\u201383.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"427_CR67","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archneur.63.5.729","volume":"63","author":"MS Okun","year":"2006","unstructured":"Okun MS, Fernandez HH, Rodriguez RL, et al. Testosterone therapy in men with Parkinson disease: results of the TEST-PD study. Arch Neurol. 2006;63(5):729\u201335.","journal-title":"Arch Neurol"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0427-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-016-0427-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-016-0427-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T16:22:29Z","timestamp":1718814149000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-016-0427-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,27]]},"references-count":67,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["427"],"URL":"https:\/\/doi.org\/10.1007\/s11940-016-0427-0","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,27]]},"article-number":"45"}}